First Hawaiian Bank Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

First Hawaiian Bank raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 56.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,550 shares of the biopharmaceutical company's stock after acquiring an additional 20,700 shares during the quarter. First Hawaiian Bank's holdings in Halozyme Therapeutics were worth $2,751,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC grew its position in Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after buying an additional 30,901 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after buying an additional 1,988,238 shares during the period. Handelsbanken Fonder AB raised its holdings in Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock worth $99,363,000 after buying an additional 209,530 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock valued at $43,002,000 after purchasing an additional 72,544 shares during the period. Institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research analyst reports. JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a report on Monday, December 30th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Up 5.0 %

HALO traded up $2.57 on Thursday, hitting $53.76. The company had a trading volume of 2,668,262 shares, compared to its average volume of 1,711,198. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The firm has a market capitalization of $6.84 billion, a P/E ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24. The stock has a fifty day simple moving average of $50.16 and a 200-day simple moving average of $54.00.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.